Msefsl

CLOSE X

Risk Disclosures on Derivatives

>9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
>On an average, loss makers registered net trading loss close to ₹ 50,000.
>Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
>Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.

Source:

1. SEBI study dated January 25, 2023 on “Analysis of Profit and Loss of Individual Traders dealing in equity Futures and Options (F&O) Segment”, wherein Aggregate Level findings are based on annual Profit/Loss incurred by individual traders in equity F&O during FY 2021-22.

GLAND PHARMA LTD.

NSE : GLANDBSE : 543245ISIN CODE : INE068V01023Industry : Pharmaceuticals & DrugsHouse : Private

BSE1728.7519.85 (+1.16 %)

PREV CLOSE ( ) 1708.90

OPEN PRICE ( ) 1708.10

BID PRICE (QTY) 0.00 (0)

OFFER PRICE (QTY) 0.00 (0)

VOLUME 4875

TODAY'S LOW / HIGH ( )1680.05 1794.40

52 WK LOW / HIGH ( )1200 2130

NSE1724.1013.6 (+0.8 %)

PREV CLOSE( ) 1710.50

OPEN PRICE ( ) 1700.50

BID PRICE (QTY) 0.00 (0)

OFFER PRICE (QTY) 1724.10 (504)

VOLUME 90957

TODAY'S LOW / HIGH( ) 1680.10 1790.00

52 WK LOW / HIGH ( )1277.8 2131

BSE NSE

1D 1M 3M 1Y 3Y 5Y

STOCK SUMMARY

Incorporation Year : 20-03 1978

Management Info

Srinivas Sadu - Chairman - Managing Director

Registered Office

Address Survey No. 143-148, 150 & 151, Near Gandimaisamma ‘x’ Roads,D. P. Pally, Dundigal, Dundigal-gandimaisamma Mandal,Medchal- Malkajgiri District,
Hyderabad,
Telangana-500043

Phone 040 30510999

Email gland@glandpharma.com / investor@glandpharma.com

Website www.glandpharma.com

Registrars Details

MUFG Intime India Pvt Ltd.

C 101, 247 Park,LBS Marg,Vikhroli (West),Mumbai

Listing : BSE, NSE

NEWS

04Mar Gland Pharma gets USFDA’s tentative no
Gland Pharma has secured tentative approval from the United States Food..

04Mar Gland Pharma informs about press relea
Pursuant to Regulation 30 read with Part A of Schedule III of the Securi..

18Feb Gland Pharma informs about analyst meet
Gland Pharma has informed that it enclosed details of schedule of the An..

18Feb Gland Pharma informs about change in m
Gland Pharma has informed that Jitendra Gangwal has been appointed as Vi..

06Feb Gland Pharma gets USFDA’s approval for
Gland Pharma has received approval from the United States Food and Drug..

Financials

Rs. in Millions

	QTR Dec 25	ANNUAL 25
Net Profit	3078.47	10897.53
Gross Profit	4124.56	14655.85
Operating Profit	4818.34	16576.93
Net Sales	11775.13	41161.49

ROLLING FORWARD P/E (EOD)

EVENT CALENDAR

peer group

Onesource Specialty (BSE) 1452.15 (6.99%)	M.Cap ( in Cr)16644.72
Emcure Pharma (BSE) 1653.60 (3.75%)	M.Cap ( in Cr)31350.53
Anthem Biosciences (BSE) 681.20 (5.44%)	M.Cap ( in Cr)38263.95
Mankind Pharma (BSE) 2040.25 (0.99%)	M.Cap ( in Cr)84227.30
Acutaas Chemicals (BSE) 2544.35 (0.75%)	M.Cap ( in Cr)20830.88

Shareholding Pattern

	PROMOTERS	51.83%
	MUTUAL FUNDS/UTI	31.42%
	NON-INSTITUTION	7.61%
	FI/BANKS/INSURANCE	1.36%
	GOVERNMENT	0%
	FII	0%

Mf Holdings

Scheme Name	Hold(%)
DSP Healthcare Fund...	5.52
ICICI Pru MNC Fund(G)	3.67
ICICI Pru Pharma He...	3.57
Nippon India Pharma...	3.27
HDFC Pharma and Hea...	3.10
UTI Healthcare Fund...	3.00
UTI MNC Fund-Reg(IDCW)	2.72

Risk Disclosures on Derivatives

Smart Quotes

GLAND PHARMA LTD.